N
RPTX

Nuveen’s Repare Therapeutics RPTX Stock Holding History

Nuveen’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,846
Closed -$235K – 3281
2023
Q1 		$235K Buy
23,846
+2,216
+10% +$25.4K ﹤0.01% 2961
2022
Q4 		$318K Sell
21,630
-188
-0.9% -$2.81K ﹤0.01% 2975
2022
Q3 		$265K Buy
21,818
+660
+3% +$8.5K ﹤0.01% 3070
2022
Q2 		$296K Buy
+21,158
New +$249K ﹤0.01% 3103

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Nuveen's RPTX Position: Q2 2023 in Review

Nuveen sold out of Repare Therapeutics (RPTX) in Q2 2023, closing a stake of 23,846 shares — an estimated $235K sold.

Nuveen first reported a position in RPTX in Q2 2022 and held it in 4 quarters. The position peaked at $318K in Q4 2022. 78 funds tracked by Wall St. Rank hold RPTX as of Q2 2023.

  • Nuveen reported no remaining Repare Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Nuveen sold 23,846 Repare Therapeutics shares in Q2 2023, an estimated $235K.
  • Nuveen first reported a position in Repare Therapeutics in Q2 2022 and held it in 4 quarters.
  • Nuveen's Repare Therapeutics position peaked at $318K in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2023.

Based on Nuveen's 13F filing for Q2 2023, filed 14 Aug 2023.